ArticleAnnals of translational medicine2023
Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden.
Michael E EggerPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.